Table 1.
Demographic and clinical variables.
| N | Responder | Remitter | Non-responder | P | V | ||
| Male, sex | (%) | 21 (42.9) | 6 (66.7) | 2 (25.0) | 13 (40.6) | .229 | 0.26 |
| Age, in years | 50.02 (13.83) | 53.11 (7.06) | 42.88 (15.78) | 50.94 (14.51) | .3361 | 0.00 | |
| BMI | 27.92 (5.67) | 28.00 (4.64) | 26.50 (4.72) | 28.25 (6.21) | .6131 | 0.02 | |
| Ketamine Treatment for: | |||||||
| MDD | 35 (71.4) | 8 (88.9) | 5 (62.5) | 22 (68.8) | .475 | 0.19 | |
| BP | 14 (28.6) | 2 (11.1) | 5 (37.5) | 7 (31.2) | .485 | 0.18 | |
| Comorbidities | .104 | 0.31 | |||||
| 1 | 21 (42.9) | 6 (66.7) | 2 (25.0) | 13 (40.6) | |||
| 2 | 10 (20.4) | 2 (22.2) | 1 (12.5) | 7 (21.9) | |||
| 3 | 4 (8.2) | 1 (11.1) | 2 (25.0) | 1 (3.1) | |||
| Hypertension | 16 (32.7) | 6 (66.7) | 3 (37.5) | 7 (21.9) | .037 | 0.37 | |
| BP | 4 (8.2) | 1 (11.1) | 2 (25.0) | 1 (3.1) | .052 | 0.66 | |
| MDD | 12 (24.5) | 5 (55.6) | 1 (12.5) | 6 (18.8) | .177 | 0.33 | |
| Diabetes mellitus | 3 (6.1) | 1 (11.1) | 2 (25.0) | 0 (0) | .021 | 0.39 | |
| Hyperlipidemia | 9 (18.4) | 3 (33.3) | 1 (12.5) | 5 (15.6) | .545 | 0.19 | |
| Post-stroke | 3 (6.1) | 1 (11.1) | 0 (0) | 2 (6.3) | .731 | 0.14 | |
| Post-myocardial infarct | 0 (0) | 0 (0) | 0 (0) | 0 (0) | - | - | |
| Epilepsy | 6 (12.2) | 0 (0) | 3 (37.5) | 3 (9.4) | .060 | 0.36 | |
| Other | 16 (32.7) | 2 (22.2) | 1 (12.5) | 13 (40.6) | .330 | 0.24 | |
| Coexisting treatment | |||||||
| TCA | 8 (16.3) | 1 (11.1) | 1 (13.5) | 6 (18.8) | 1.000 | 0.09 | |
| Clomipramine | 4 (8.2) | 0 (0) | 1 (12.5) | 3 (9.4) | .789 | 0.15 | |
| Amitriptiline | 4 (8.2) | 1 (11.1) | 0 (0) | 3 (9.4) | 1.000 | 0.13 | |
| SSRI total | 23 (46.9) | 5 (55.6) | 2 (25.0) | 16 (50.0) | .413 | 0.20 | |
| Fluvoxamine | 1 (2.0) | 0 (0) | 0 (0) | 1 (3.1) | 1.000 | 0.11 | |
| Paroxetine | 5 (10.2) | 1 (11.1) | 0 (0) | 4 (12.5) | .813 | 0.15 | |
| Fluoxetine | 8 (16.3) | 2 (22.2) | 0 (0) | 6 (18.8) | .534 | 0.20 | |
| Sertraline | 3 (6.1) | 1 (11.1) | 0 (0) | 2 (6.3) | .731 | 0.14 | |
| Citalopram | 4 (8.2) | 0 (0) | 2 (25.0) | 2 (6.3) | .179 | 0.29 | |
| Escitalopram | 2 (4.1) | 1 (11.1) | 0 (0) | 1 (3.1) | .578 | 0.18 | |
| SNRI total | 11 (22.4) | 2 (22.2) | 2 (25.0) | 7 (21.9) | 1.000 | 0.03 | |
| Venlafaxeine | 8 (16.3) | 1 (11.1) | 1 (12.5) | 6 (18.8) | 1.000 | 0.10 | |
| Duloxetine | 3 (6.1) | 1 (11.1) | 1 (12.5) | 1 (3.1) | .273 | 0.17 | |
| Other | .749 | 0.14 | |||||
| 1 | 15 (30.6) | 4 (44.4) | 2 (25.0) | 9 (28.1) | |||
| 2 | 3 (6.1) | 0 (0) | 1 (12.5) | 2 (6.3) | |||
| Mirtazapine | 9 (18.4) | 2 (22.2) | 1 (12.5) | 6 (18.8) | 1.000 | 0.08 | |
| Mianserine | 3 (6.1) | 1 (11.1) | 0 (0) | 2 (6.3) | .731 | 0.14 | |
| Trazodone | 4 (8.2) | 1 (11.1) | 1 (12.5) | 2 (6.3) | .432 | 0.10 | |
| Bupropione | 3 (6.1) | 0 (0) | 1 (12.5) | 2 (6.3) | .488 | 0.15 | |
| Vortioxetine | 2 (4.1) | 0 (0) | 1 (12.5) | 1 (3.1) | .333 | 0.20 | |
| Antipsychotic medication | .806 | 0.15 | |||||
| 1 | 12 (24.5) | 2 (22.2) | 1 (12.5) | 9 (28.1) | |||
| 2 | 5 (10.2) | 0 (0) | 1 (12.5) | 4 (12.5) | |||
| Aripiprazole | 6 (12.2) | 0 (0) | 1 (12.5) | 5 (15.6) | .685 | 0.18 | |
| Quetiapine | 10 (20.4) | 1 (11.1) | 1 (12.5) | 8 (25.0) | .668 | 0.16 | |
| Olanzpiane | 5 (10.2) | 1 (11.1) | 1 (12.5) | 3 (9.4) | 1.000 | 0.04 | |
| Risperidone | 1 (2.0) | 0 (0) | 0 (0) | 1 (3.1) | 1.000 | 0.11 | |
| Mood stabilizers | .348 | 0.29 | |||||
| 1 | 15 (30.6) | 2 (22.2) | 4 (50.0) | 9 (28.1) | |||
| 2 | 6 (12.2) | 1 (11.1) | 0 (0) | 5 (15.6) | |||
| 3 | 1 (2.0) | 0 (0) | 1 (12.5) | 0 (0) | |||
| lithium | 5 (10.2) | 0 (0) | 1 (12,5) | 4 (12.5) | .643 | 0.16 | |
| valproate | 9 (18.4) | 2 (22.2) | 3 (37.5) | 4 (12.5) | .160 | 0.24 | |
| lamotrigine | 7 (14.3) | 1 (11.1) | 1 (12.5) | 5 (15.6) | 1.000 | 0.05 |
Mood stabilizers – based on Young (2004).[32]
BMI = body mass index, BP = bipolar disorder, MDD = major depressive disorder, SNRI = selective serotonin-noradrenaline reuptake inhibitors, SSRI = selective serotonin reuptake inhibitors, TCA = other than mentioned tricyclic antidepressants.